Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Kalvista Pharmaceuticals Inc (NQ: KALV ) 11.39 -0.19 (-1.64%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Kalvista Pharmaceuticals Inc < Previous 1 2 3 4 5 6 7 Next > Recap: KalVista Pharma Q3 Earnings March 11, 2024 Via Benzinga KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update March 11, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present HAE Attack Journey Data at 2024 HAEi Regional Conference Americas March 08, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer March 07, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Insiders Buying Dorian LPG And 2 Other Stocks January 17, 2024 Although U.S. stocks closed lower on Tuesday, there were a few notable insider trades. Via Benzinga KalVista Pharmaceuticals to Participate in the Leerink Partners 2024 Global Biopharma Conference March 06, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 04, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting February 27, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Presents Additional Phase 3 KONFIDENT Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting February 26, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat February 20, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire KalVista Pharmaceuticals to Present Phase 3 Sebetralstat Data at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting February 16, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire 12 Health Care Stocks Moving In Thursday's Pre-Market Session February 15, 2024 Via Benzinga KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants February 15, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire 12 Health Care Stocks Moving In Wednesday's After-Market Session February 14, 2024 Via Benzinga KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants February 14, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday February 14, 2024 Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Via Benzinga What's Going With Hereditary Angioedema-Focused KalVista Pharmaceuticals Stock On Tuesday? February 13, 2024 Results from KalVista Pharmaceuticals' Phase 3 KONFIDENT trial. Sebetralstat, an oral on-demand therapy, shows efficacy for hereditary angioedema. Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session February 13, 2024 Via Benzinga KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema February 13, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Insiders Buying Monro And 3 Other Stocks February 09, 2024 Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. Via Benzinga $10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying February 02, 2024 Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. Via Benzinga KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 02, 2024 From KalVista Pharmaceuticals, Inc. Via Business Wire Over $1M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying January 30, 2024 Although U.S. stocks closed higher on Monday, there were a few notable insider trades. Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session January 22, 2024 Via Benzinga $230M Bet On Talos Energy? Check Out These 4 Stocks Insiders Are Buying January 22, 2024 Although U.S. stocks closed higher on Friday, there were a few notable insider trades. Via Benzinga Insiders Buying KalVista Pharmaceuticals And 3 Other Stocks January 11, 2024 Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades. Via Benzinga $6.5M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying January 08, 2024 Although U.S. stocks closed slightly higher on Friday, there were a few notable insider trades. Via Benzinga Around $2.4M Bet On HighPeak Energy? Check Out These 4 Stocks Insiders Are Buying January 02, 2024 Although U.S. stocks closed lower on Friday, there were a few notable insider trades. Via Benzinga KalVista Pharmaceuticals Announces Publication of First Oral Factor XIIa Data in Frontiers in Pharmacology December 20, 2023 From KalVista Pharmaceuticals, Inc. Via Business Wire KALV Stock Earnings: KalVista Pharma Misses EPS for Q2 2024 December 07, 2023 KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the second quarter of 2024. Via InvestorPlace < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.